Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. The company's key product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of farnesyl transferase. The company's second product candidate is KO-947, a selective small molecule inhibitor of extracellular signal related kinase, which the company is developing as a potential treatment for patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway. The company's third product candidate is KO-539, a selective small molecule inhibitor of the menin-mixed lineage leukemia, protein-protein interaction.

Next Biometrics Group is a holding company. Co., through its subsidiaries, is engaged in the research, development, manufacture, and commercialization of fingerprint technology and products. Co. uses thermal conductivity to read the fingerprint as opposed to capacitive or optical sensing used by most competitors. Due to this, Co.'s fingerprint sensors have a production cost lower than comparable quality fingerprint sensors. Co. offers fingerprint sensor modules for use in smartphones, tablets, notebooks and accessories, corporate access control, time and attendance, usb-sensors, smartcard readers, secure tokens, and physical access control systems.